Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Sep 10

PMID 34503296

Citations 5

Authors

Maximillian Viera

George Wai Cheong Yip

Han-Ming Shen

Gyeong Hun Baeg

Boon Huat Bay

Affiliations

Soon will be listed here.

Abstract

Metastasis is the main cause of mortality in breast cancer patients. There is an unmet need to develop therapies that can impede metastatic spread. Precision oncology has shown great promise for the treatment of cancers, as the therapeutic approach is tailored to a specific group of patients who are likely to benefit from the treatment, rather than the traditional approach of "one size fits all". CD82, also known as KAI1, a glycoprotein belonging to the tetraspanin family and an established metastasis suppressor, could potentially be exploited to hinder metastases in breast cancer. This review explores the prospect of targeting CD82 as an innovative therapeutic approach in precision medicine for breast cancer patients, with the goal of preventing cancer progression and metastasis. Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropriate treatment scheme tailored towards restoring the levels of CD82 in this group of patients. Proposed precision treatment regimens include current modalities of treating breast cancer, in combination with either clinically approved drugs that could restore the levels of CD82, CD82 peptide mimics or non-coding RNA-based therapeutics.

Citing Articles

Addressing the mean-variance relationship in spatially resolved transcriptomics data with .

Shah K, Guo B, Hicks S bioRxiv. 2024; .

PMID: 39574747 PMC: 11580860. DOI: 10.1101/2024.11.04.621867.

Tspan protein family: focusing on the occurrence, progression, and treatment of cancer.

Zhang H, Song Q, Shang K, Li Y, Jiang L, Yang L Cell Death Discov. 2024; 10(1):187.

PMID: 38649381 PMC: 11035590. DOI: 10.1038/s41420-024-01961-0.

Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors.

Komlosh P, Chen J, Childs-Disney J, Disney M, Canaani D Sci Rep. 2023; 13(1):20420.

PMID: 37990044 PMC: 10663508. DOI: 10.1038/s41598-023-47478-x.

Molecular interaction of metastasis suppressor genes and tumor microenvironment in breast cancer.

Supuramanian S, Dsa S, Harihar S Explor Target Antitumor Ther. 2023; 4(5):912-932.

PMID: 37970212 PMC: 10645471. DOI: 10.37349/etat.2023.00173.

From Fruit Waste to Medical Insight: The Comprehensive Role of Watermelon Rind Extract on Renal Adenocarcinoma Cellular and Transcriptomic Dynamics.

Reddy C, Natarajan P, Nimmakayala P, Hankins G, Reddy U Int J Mol Sci. 2023; 24(21).

PMID: 37958599 PMC: 10647773. DOI: 10.3390/ijms242115615.

References

Forterre A, Komuro H, Aminova S, Harada M . A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. Cancers (Basel). 2020; 12(7). PMC: 7408939. DOI: 10.3390/cancers12071852. View

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

Guo X, Friess H, Graber H, Kashiwagi M, Zimmermann A, Korc M . KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res. 1996; 56(21):4876-80. View

He B, Liu L, Cook G, Grgurevich S, Jennings L, Zhang X . Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha6-mediated cell adhesion. J Biol Chem. 2004; 280(5):3346-54. DOI: 10.1074/jbc.M406680200. View

Vignoli A, Risi E, McCartney A, Migliaccio I, Moretti E, Malorni L . Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. Int J Mol Sci. 2021; 22(9). PMC: 8124948. DOI: 10.3390/ijms22094687. View

Rahman M, Brane A, Tollefsbol T . MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer. Cells. 2019; 8(10). PMC: 6829616. DOI: 10.3390/cells8101214. View

Jackson P, Marreiros A, Russell P . KAI1 tetraspanin and metastasis suppressor. Int J Biochem Cell Biol. 2004; 37(3):530-4. DOI: 10.1016/j.biocel.2004.08.009. View

Zhang H, Sun D, Mao L, Zhang J, Jiang L, Li J . MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. Biochem Biophys Res Commun. 2015; 465(4):702-13. DOI: 10.1016/j.bbrc.2015.08.053. View

Zhao Y, Sato Y, Isaji T, Fukuda T, Matsumoto A, Miyoshi E . Branched N-glycans regulate the biological functions of integrins and cadherins. FEBS J. 2008; 275(9):1939-48. DOI: 10.1111/j.1742-4658.2008.06346.x. View

10.

Giannone G, Milani A, Ghisoni E, Genta S, Mittica G, Montemurro F . Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series. Breast. 2018; 38:160-164. DOI: 10.1016/j.breast.2018.01.006. View

11.

Abraham J, Montero A, Jankowitz R, Salkeni M, Beumer J, Kiesel B . Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. J Clin Oncol. 2019; 37(29):2601-2609. PMC: 6784849. DOI: 10.1200/JCO.19.00858. View

12.

Zhu C, He L, Zhou X, Nie X, Gu Y . Sulfatase 2 promotes breast cancer progression through regulating some tumor-related factors. Oncol Rep. 2015; 35(3):1318-28. PMC: 4750748. DOI: 10.3892/or.2015.4525. View

13.

Voutsadakis I . A Systematic Review and Pooled Analysis of Studies of Oral Etoposide in Metastatic Breast Cancer. Eur J Breast Health. 2018; 14(1):10-16. PMC: 5758057. DOI: 10.5152/ejbh.2017.3563. View

14.

Zhou X, Wang M . Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis. Genet Mol Res. 2015; 14(4):17059-67. DOI: 10.4238/2015.December.16.6. View

15.

Zeng T, Zheng B, Zheng W, Chen C . CD82/KAI1 inhibits invasion and metastasis of esophageal squamous cell carcinoma via TGF-β1. Eur Rev Med Pharmacol Sci. 2018; 22(18):5928-5937. DOI: 10.26355/eurrev_201809_15922. View

16.

Shi P, Chen C, Li X, Wei Z, Liu Z, Liu Y . MicroRNA‑124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3. Mol Med Rep. 2019; 19(5):3667-3675. PMC: 6472193. DOI: 10.3892/mmr.2019.10044. View

17.

Long J, Luo J, Yin X . MiR-338-5p promotes the growth and metastasis of malignant melanoma cells via targeting CD82. Biomed Pharmacother. 2018; 102:1195-1202. DOI: 10.1016/j.biopha.2018.03.075. View

18.

Cohen P, Cross D, Janne P . Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021; 20(7):551-569. PMC: 8127496. DOI: 10.1038/s41573-021-00195-4. View

19.

Zhang W, Guan X, Tang J . The long non-coding RNA landscape in triple-negative breast cancer. Cell Prolif. 2020; 54(2):e12966. PMC: 7848969. DOI: 10.1111/cpr.12966. View

20.

Bouchie A . First microRNA mimic enters clinic. Nat Biotechnol. 2013; 31(7):577. DOI: 10.1038/nbt0713-577. View